Emerging resistance to azoles and echinocandins: Clinical relevance and laboratory detection

Current Fungal Infection Reports

Volumn 4, Issue 3, 2010, Pages 186-195

  Espinel Ingroff, Ana ^a   Pfaller, Michael ^b   Cantón, Emilia ^c   Pemán, Javier ^d  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c Hospital Universitario La Fe ^*  (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Aspergillus spp.; Candida spp.; Clinical breakpoints; Clinical relevance; ECVs; Emerging triazole and echinocandin resistance; Molds; Triazole and echinocandin resistance; Yeasts and molds

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; CDR PROTEIN; ECHINOCANDIN; ERG11 PROTEIN; ERGOSTEROL; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; MULTIDRUG RESISTANCE PROTEIN; POSACONAZOLE; PROTEIN; STEROL 14ALPHA DEMETHYLASE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANALYTICAL PARAMETERS; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; ASPERGILLUS; BROTH DILUTION; CANDIDA; CANDIDEMIA; CANDIDIASIS; CLINICAL BREAKPOINT; CROSS RESISTANCE; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DISK DIFFUSION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; EPIDEMIOLOGIC CUTOFF VALUE; FUNGAL DETECTION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOULD; NONHUMAN; POINT MUTATION; PSEUDALLESCHERIASIS; REVIEW;

EID: 79952101900     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-010-0026-6     Document Type: Review

References (53)

1. Espinel-Ingroff A: Mechanisms of resistance to antifungal agents: Yeasts and filamentous fungi. Rev Iberoam Micol 2008, 25:99-104. This paper provides a comprehensive review of the literature (2005-2008) regarding molecular mechanisms of resistance and their correlation with in vitro and in vivo results for both yeasts and molds.
2. Clinical and Laboratory Standards Institute: Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 3rd ed. CLSI document M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2008. This document describes new guidelines for testing yeasts with the echinocandins.
3. rd ed. CLSI document M27-S3. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
4. Clinical and Laboratory Standards Institute: Method for antifungal disk diffusion susceptibility testing of yeasts. Approved standard, 2nd ed. CLSI M44-A2 document. Wayne, PA: Clinical and Laboratory Standards Institute; 2009.
5. Clinical and Laboratory Standards Institute: Zone diameter interpretive standards, corresponding minimal inhibitory concentration (MIC) interpretive breakpoints, and quality control limits for antifungal disk diffusion susceptibility testing of yeasts. Informational supplement, 3rd ed. CLSI M44-S3 document. Wayne, PA: Clinical and Laboratory Standards Institute; 2009.
6. Rodriguez-Tudela JL, Arendrup MC, Barchiesi F, et al.: EUCAST definitive document EDef7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 2008, 14:398-405. (Pubitemid 351356536)
7. Rodriguez-Tudela JL, Donnelly JP, Arendrup MC, et al.: EUCAST technical note on fluconazole. Clin. Microbiol Infect 2008, 14:193-195.
8. Rodriguez-Tudela JL, Donnelly JP, Arendrup MC, et al.: EUCAST technical note on voriconazole. Clin Microbiol Infect 2008, 14:985-987.
9. Clinical and Laboratory Standards Institute: Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard, 2nd ed. CLSI document M38-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
10. Clinical and Laboratory Standards Institute: Method for antifungal disk diffusion susceptibility testing of non-dermatophyte filamentous fungi. Approved standard, CLSI M51-A document. Wayne, PA: Clinical and Laboratory Standards Institute; 2010. This recently published document describes the disk diffusion testing guideline for molds and triazoles, amphotericin B, and caspofungin.
11. Clinical and Laboratory Standards Institute: Performance standards for antifungal disk diffusion susceptibility testing of non-dermatophyte filamentous fungi. Informational supplement, CLSI M51-S1 document. Wayne, PA: Clinical and Laboratory Standards Institute; 2010.
12. Rodriguez-Tudela JL, Donnelly JP, Arendrup MC, et al.: EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin Microbiol Infect 2008, 14:982-984.
13. Arendrup MC, Garcia-Effron G, Lass-Florl C, et al.: Echinocandins susceptibility testing of Candida species: comparison of EUCAST Edef 7.1, CLSI M27-A3, Etest, disk diffusion and agar dilution methods with RPMI and isoSensitets media. Antimicrob Agents Chemother 2010, 52:426-439.
14. Dalhoff A, Ambrose PG, Mouton JW: A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. Infection 2009, 37:296-305.
15. Espinel-Ingroff A: In vitro susceptibility testing: when, where, and what to use. J Invasive Fungal Infect 2008, 2:52-61. This review describes in detail reference and alternative methods for susceptibility testing of yeasts and molds and discusses their clinical relevance (or the lack of it).
16. Magill SS, Shields C, Sears CL, et al.: Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol 2006, 44:529-535. (Pubitemid 43222248)
17. Pfaller MA, Andes D, Diekema DJ, et al.: Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Update 2010 (in press). This article provides species-specific CBPs and ECVs for fluconazole and Candida that are similar to those established by EUCAST and describes excellent data regarding the correlation of these cutoffs with clinical outcome.
18. Pfaller MA, Diekema DJ, Gibbs DL, et al.: Results from the ARTEMIS Disk Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010, 48:1366-1377.
19. Cuesta I, Bielza C, Cuenca-Estrella M, et al.: Evaluation by data mining techniques of fluconazole breakpoints established by the Clinical and Laboratory Standards Institute (CLSI), and its comparison with those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Antimicrob Agents Chemother 2010, 54:1541-1546. Comparison of CLSI and EUCAST fluconazole CBPs is provided by data mining analyses.
20. Baddley JW, Patel M, Bhavnani SM, et al.: Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother 2008, 52:3022-3028.
21. Pfaller M, Boyken L, Hollis R, et al.: Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24 hour CLSI broth microdilution method. To be presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA; September 12-15, 2010. Species-specific posaconazole and voriconazole ECVs for Candida are described; these new susceptibility cutoffs can be helpful in monitoring the emerging resistance of Candida isolates to these two agents.
22. Pfaller MA, Diekema DJ, Gibbs DL, et al.: Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis 2010, 67:162-171. Data regarding regional triazole resistance of C. glabrata are provided.
23. Fleischhacker M, Pasligh J, Moran G, Ruhnke M: Longitudinal genotyping of Candida dubliniensis isolates reveals strain maintenance, microevolution, and the emergence of itraconazole resistance. J Clin Microbiol 2010, 48:1643-1650. Emerging itraconazole resistance among C. dubliniensis isolates is reported.
24. Pfaller MA, Diekema DJ, Gibbs DL, et al.: Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of non-candidal yeast species to fluconazole and voriconazole determined by the CLSI standardized disk diffusion testing. J Clin Microbiol 2009, 47:117-123.
25. Baixench M-T, Aoun N, Desnos-Ollivier M, et al.: Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother 2007, 59:1076-1083. (Pubitemid 47073317)
26. Garcia-Effron G, Park S, Perlin DS: Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother 2009, 53:112-122. These authors demonstrated that the available susceptible echinocandin CBP was not adequate for C. albicans versus either micafungin or anidulafungin
27. Cleary JD, Garcia-Effron G, Chapman SW, et al.: Reduced Candida glabrata susceptibility secondary to an FSK1 mutation developed during candidemia treatment. Antimicrob Agents Chemother 2008, 52:2263-2265. (Pubitemid 351758575)
28. Garcia-Effron G, Lee S, Park S, et al.: Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-β-D-glucan synthase: implications for the existing breakpoint. Antimicrob Agents Chemother 2009, 53:3690-3699. These authors demonstrated that the available susceptible echinocandin CBP was not adequate for C. glabrata versus either micafungin or anidulafungin.
29. Chapeland-Leclerc F, Hennequin C, Papon N, et al.: Acquisition of flucytosine, azole and caspofungin resistance in Candida glabrata bloodstream infection. Antimicrob Agents Chemother 2010, 54:1360-1362.
30. Pfaller MA, Boyken L, Hollis RJ, et al.: Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J Clin Microbiol 2010, 48:52-56. These authors for the first time defined wild-type echinocandin MIC populations and proposed ECVs for Candida spp. and the echinocandins.
31. Pfaller MA, Diekema DJ, Andes D, et al.: Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at speciesspecific interpretive criteria. Drug Resist Updat 2010 (in press). In this excellent and comprehensive article, the authors propose the adjustment of echinocandin CBPs from the current CLSI single susceptible cutoff to species-specific cutoffs. These CBPs can be useful for detecting resistance of Candida spp. isolates to this class of antifungal drugs.
32. Colombo AL, Ngai Al, Bourque M, et al.: Caspofungin use in patients with invasive candidiasis caused common non-albicans Candida species: review of the caspofungin database. Antimicrob Agents Chemother 2010, 54:1864-1871. The favorable use of caspofungin for non-C. albicans species is reported.
33. Thompson GR, Wiederhold NP, Vallor AC, et al.: Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother 2008, 52:3783-3785.
34. Angiolella L, Stringaro AR, De Bernardis F, et al.: Increased virulence and its phenotypic traits in drug-resistant strains of Candida albicans. Antimicrob Agents Chemother 2008, 52:927-936. (Pubitemid 351358372)
35. Andes D, Diekema DJ, Pfaller MA, et al.: In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother 2010, 54:2497-2506.
36. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, et al.: A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 2007, 51: 1897-1904. (Pubitemid 46903071)
37. Krishnan-Natesan S, Chandrasekar PH, Alangaden GJ, Manavathu EK: Molecular characterisation of cyp51A and cyp51B genes coding for P450 14alpha-lanosterol demethylases A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus. Int J Antimicrob Agents 2008, 32:519-524. This article provides the first evidence of the association of gene mutations and voriconazole resistance in A. fumigatus.
38. Howard SJ, Cerar D, Anderson MJ, et al.: Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009, 15:1068-1076.
39. Snelders E, van der Lee HA, Kuijpers J, et al.: Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 2008, 5(11):e219.
40. Snelders E, Karajzyk A, Shaftenaar G, et al.: Azole resistance of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. Antimicrob Agents Chemother 2010, 54:2425-2430.
41. Verweij PE, Mellado E, Melchers WJG: Multiple-triazoleresistance aspergillosis. N Engl J Med 2007, 356:1481-1483.
42. Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E, et al.: Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 2008, 52:2468-2472. The EUCAST provided ECVs for A. fumigatus and the triazoles for the first time in this article.
43. Pfaller MA, Diekema DJ, Ghannoum MA, et al.: Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J Clin Microbiol 2009, 47:3142-3146. ECVs for A. fumigatus and the triazoles are provided in this article by the CLSI.
44. Verweij PE, Howard SJ, Melchers WJG, et al.: Azole resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat 2009, 12:141-147. Non-CBPs for A. fumigatus and the triazoles are provided in this article.
45. Espinel-Ingroff A, Diekema DJ, Fothergill A, et al.: Wild-type distributions and epidemiological cutoff values for the triazoles and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol 2010 (in press). For the first time, ECVs for non-A. fumigatus species and the triazoles are proposed in this article.
46. Baddley JW, Marr KA, Andes DR, et al.: Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the transplant-associated infection survey network. J Clin Microbiol 2009, 47:3271-3275.
47. Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, et al.: Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. Antimicrob Agents Chemother 2009, 53:4514-4517.
48. Mavridou E, Bruggemann RJM, Melchers WJG, et al.: Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother 2010, 54:860-865.
49. Rocha EM, Garcia-Effron G, Park S, et al.: A ser67Pro substitution in Fk51p confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 2007, 51:4174-4176. A similar mutation to that associated with echinocandin resistance in C. albicans was also associated with resistance to echinocandins in A. fumigatus.
50. Katiyar SK, Edlind TD: Role for Fks1 in the intrinsic echinocandin resistance of Fusarium solani as evidenced by hybrid expression in Saccharomyces cerevisiae. Antimicrob Agents Chemother 2009, 53:1772-1778.
51. Almyroudis NG, Sutton DA, Fothergill AW, et al.: In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007, 51:587-590. This paper provides in vitro data for a large number of mucoraceous isolates.
52. Espinel-Ingroff A, Johnson E, Troke PF: Activity of voriconazole, itraconazole and amphotericin B in vitro against 595 moulds from patients in the voriconazole Phase III clinical studies. J Antimicrob Chemother 2008, 61:616-620. (Pubitemid 351321136)
53. Troke P, Aguirrebengoa K, Arteaga C, et al.: Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother 2008, 52:1743-1750. (Pubitemid 351614668)